QuantAbundanceAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

35,144 signal articles · 107 in last 24h · 178,660 total before filter · latest 1h ago

107last 24h

3126last 7d

511● bullish (7d)

311● bearish (7d)

227publishers

All Macro103 Earnings1820 M&A172 Regulatory23 Product26 Analyst28

✕ clear all filtersticker: RXRXSentiment:bullish neutral bearish show all (incl. clickbait)

Simply Wall St.3d agoneutral

Is Recursion Pharmaceuticals (RXRX) A Bargain After Q3 Earnings And Clinical Updates?

Zacks4d agoneutral

RXRX Q3 Earnings Call Highlights Clinical Progress and Cash Runway

Moby5d agoneutral

Recursion Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary

Motley Fool5d agoneutral

Recursion (RXRX) Q3 2026 Earnings Call Transcript

MarketBeat5d agoneutral

What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call

Zacks5d agobullish

Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues

Associated Press5d agoneutral

Recursion Pharmaceuticals: Q3 Earnings Snapshot

Zacks6d agobullish

Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue Estimates

GlobeNewswire6d agoneutral

Recursion Appoints Fred Hassan as Chair of the Board

GuruFocus.com6d agoneutral

Earnings To Watch: Recursion Pharmaceuticals Inc (RXRX) Q3 2026 -- GF Value Sees 33% Downside

Motley Fool8d agoneutral

1 Big Winner and 1 Loser From the Upcoming Anthropic IPO

GuruFocus.com9d agoneutral

Earnings To Watch: Recursion Pharmaceuticals Inc (RXRX) Q3 2026 -- GF Value Sees 35% Downside

Zacks10d agoneutral

Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?

Zacks11d agobullish

Recursion Pharmaceuticals (RXRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

TheStreet45d agoneutral

Analysts move HubSpot 29 places higher in power ranking

Zacks65d agoneutral

Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?

Motley Fool88d agoneutral

Recursion (RXRX) Q2 2026 Earnings Call Transcript

24/7 Wall St.89d agobullish

The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)

Moby95d agoneutral

Recursion Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary

MarketBeat95d agoneutral

Recursion Pharmaceuticals Q2 Earnings Call Highlights

Zacks95d agobearish

Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Misses Revenue Estimates

Zacks156d agoneutral

Recursion Pharmaceuticals (RXRX) Up 16.2% Since Last Earnings Report: Can It Continue?

Motley Fool185d agoneutral

Recursion (RXRX) Q1 2026 Earnings Transcript

MarketBeat186d agoneutral

Recursion Pharmaceuticals Q1 Earnings Call Highlights

Zacks186d agoneutral

Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Lags Revenue Estimates